Levonorg-Eth Estrad Eth Estrad (L-Norgest/E.Estradiol-E.Estrad) Patent Expiration, LOE Window & CMS Spending

Levonorg-Eth Estrad Eth Estrad (L-Norgest/E.Estradiol-E.Estrad) by Myl-Via/Xiromed: Off-Patent Genericized (AB Competition), 0 AB generics, $634K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMyl-Via/Xiromed
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$634K
2024 Medicare Part D Spend$111K
2024 Medicaid Spend$523K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel